**12/6/17 | NEWS UPDATE GT Biopharma, Inc. Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis Autoimmune Muscular Disease**
The recent $12 billion acquisition of Kite Pharma, Inc. by big-pharma giant, Gilead Sciences has biotech investors hungry for the next big buyout target.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.